Sign inJoin waitlistJoin the waitlist

Rachel Sanborn

, Member · Providence Health & Services - Oregon

Credentials: · · ·

History

Providence Health & Services - Oregon
Present

Oregon Health & Science University School of Medicine
2002–2004
Internal Medicine
University of Illinois College of Medicine at Chicago
1999–2002
Oregon Health & Science University School of Medicine
1995–1999

Research

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2,…
The Lancet Oncology · 2015 · 1,216 citations
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Journal of Clinical Oncology · 2016 · 673 citations
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Journal of Clinical Oncology · 2021 · 551 citations

AS
Alexander Spira
12 papers
Joshua Sabari
10 papers
RK
Roland Knoblauch
9 papers
Catherine Shu
6 papers
Jonathan Goldman
6 papers
Joshua Bauml
6 papers
MB
Mahadi Baig
6 papers
Aaron Mansfield
5 papers
Karen Reckamp
5 papers
LH
Leora Horn
5 papers
MT
Meena Thayu
5 papers
MJ
Melissa Johnson
5 papers

Clinical trials

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
Rachel Sanborn
2020–2024
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Principal investigator · Completed · Phase 1
Heat Biologics
2019–2022
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Active not recruiting · Phase 1, Phase 2
Providence Health & Services
2015–2026
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Principal investigator · Completed · Phase 1, Phase 2
MedImmune LLC
2014–2020